Works matching DE "LECANEMAB"

Results: 99

Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 12, p. 2111, doi. 10.1002/psp4.13224

By:

Majid, Oneeb;
Cao, Youfang;
Willis, Brian A.;
Hayato, Seiichi;
Takenaka, Osamu;
Lalovic, Bojan;
Sreerama Reddy, Sree Harsha;
Penner, Natasha;
Reyderman, Larisa;
Yasuda, Sanae;
Hussein, Ziad

Publication type:

Article

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 12, p. 1578, doi. 10.1002/psp4.12862

By:

Hayato, Seiichi;
Takenaka, Osamu;
Sreerama Reddy, Sree Harsha;
Landry, Ishani;
Reyderman, Larisa;
Koyama, Akihiko;
Swanson, Chad;
Yasuda, Sanae;
Hussein, Ziad

Publication type:

Article

Lecanemab: First Approval.

Published in:

Drugs, 2023, v. 83, n. 4, p. 359, doi. 10.1007/s40265-023-01851-2

By:

Hoy, Sheridan M.

Publication type:

Article

Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG.

Published in:

Annals of Clinical & Translational Neurology, 2024, v. 11, n. 12, p. 3192, doi. 10.1002/acn3.52227

By:

Bellier, Jean‐Pierre;
Román Viera, Andrea M.;
Christiano, Caitlyn;
Anzai, Juliana A. U.;
Moreno, Stephanie;
Campbell, Emily C.;
Godwin, Lucas;
Li, Amy;
Chen, Alan Y.;
Alam, Sarah M.;
Saba, Adriana;
Yoo, Han Bin;
Yang, Hyun‐Sik;
Chhatwal, Jasmeer P.;
Selkoe, Dennis J.;
Liu, Lei

Publication type:

Article

Donanemab: Not two without a third.

Published in:

Advances in Clinical & Experimental Medicine, 2023, v. 32, n. 10, p. 1085, doi. 10.17219/acem/172673

By:

Kurkinen, Markku

Publication type:

Article

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.

Published in:

Advances in Clinical & Experimental Medicine, 2023, v. 32, n. 9, p. 943, doi. 10.17219/acem/171379

By:

Kurkinen, Markku

Publication type:

Article

Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection.

Published in:

Neurology & Therapy, 2025, v. 14, n. 1, p. 1, doi. 10.1007/s40120-024-00675-w

By:

Martorana, Alessandro;
Bonomi, Chiara Giuseppina;
Di Donna, Martina Gaia;
Motta, Caterina

Publication type:

Article

Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.

Published in:

Neurology & Therapy, 2023, v. 12, n. 4, p. 1133, doi. 10.1007/s40120-023-00492-7

By:

Igarashi, Ataru;
Azuma, Mie Kasai;
Zhang, Quanwu;
Ye, Weicheng;
Sardesai, Aditya;
Folse, Henri;
Chavan, Ameya;
Tomita, Kiyoyuki;
Tahami Monfared, Amir Abbas

Publication type:

Article

A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.

Published in:

Neurology & Therapy, 2023, v. 12, n. 3, p. 863, doi. 10.1007/s40120-023-00473-w

By:

Tahami Monfared, Amir Abbas;
Ye, Weicheng;
Sardesai, Aditya;
Folse, Henri;
Chavan, Ameya;
Aruffo, Elena;
Zhang, Quanwu

Publication type:

Article

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Published in:

Neurology & Therapy, 2023, v. 12, n. 3, p. 795, doi. 10.1007/s40120-023-00460-1

By:

Tahami Monfared, Amir Abbas;
Ye, Weicheng;
Sardesai, Aditya;
Folse, Henri;
Chavan, Ameya;
Kang, Kang;
Zhang, Quanwu

Publication type:

Article

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Published in:

Neurology & Therapy, 2022, v. 11, n. 3, p. 1285, doi. 10.1007/s40120-022-00373-5

By:

Tahami Monfared, Amir Abbas;
Tafazzoli, Ali;
Chavan, Ameya;
Ye, Weicheng;
Zhang, Quanwu

Publication type:

Article

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Published in:

Neurology & Therapy, 2022, v. 11, n. 2, p. 863, doi. 10.1007/s40120-022-00350-y

By:

Tahami Monfared, Amir Abbas;
Tafazzoli, Ali;
Ye, Weicheng;
Chavan, Ameya;
Zhang, Quanwu

Publication type:

Article

Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43933-5

By:

Solopova, Elena;
Romero-Fernandez, Wilber;
Harmsen, Hannah;
Ventura-Antunes, Lissa;
Wang, Emmeline;
Shostak, Alena;
Maldonado, Jose;
Donahue, Manus J.;
Schultz, Daniel;
Coyne, Thomas M.;
Charidimou, Andreas;
Schrag, Matthew

Publication type:

Article

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance.

Published in:

Alzheimer's Research & Therapy, 2025, v. 17, n. 1, p. 1, doi. 10.1186/s13195-025-01699-6

By:

Donati, Monia;
Boccia, Angela;
De Ponti, Fabrizio;
Poluzzi, Elisabetta;
Raschi, Emanuel

Publication type:

Article

Reply: [Post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system].

Published in:

Alzheimer's Research & Therapy, 2025, v. 17, n. 1, p. 1, doi. 10.1186/s13195-025-01728-4

By:

Xing, Xiaoxuan;
Wang, Ke;
Dong, Xianzhe

Publication type:

Article

Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.

Published in:

Alzheimer's Research & Therapy, 2025, v. 17, n. 1, p. 1, doi. 10.1186/s13195-024-01669-4

By:

Xing, Xiaoxuan;
Zhang, Xiaotong;
Wang, Ke;
Wang, Zhizhou;
Feng, Yingnan;
Li, Xiaoxi;
Hua, Yiming;
Zhang, Lan;
Dong, Xianzhe

Publication type:

Article

Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab.

Published in:

2024

By:

Ji, Sung;
Rosenbloom, Michael

Publication type:

Case Study

Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.

Published in:

2024

By:

Honig, Lawrence S.;
Sabbagh, Marwan N.;
van Dyck, Christopher H.;
Sperling, Reisa A.;
Hersch, Steven;
Matta, Andre;
Giorgi, Luigi;
Gee, Michelle;
Kanekiyo, Michio;
Li, David;
Purcell, Derk;
Dhadda, Shobha;
Irizarry, Michael;
Kramer, Lynn

Publication type:

Correction Notice

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13195-024-01441-8

By:

Honig, Lawrence S.;
Sabbagh, Marwan N.;
van Dyck, Christopher H.;
Sperling, Reisa A.;
Hersch, Steven;
Matta, Andre;
Giorgi, Luigi;
Gee, Michelle;
Kanekiyo, Michio;
Li, David;
Purcell, Derk;
Dhadda, Shobha;
Irizarry, Michael;
Kramer, Lynn

Publication type:

Article

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13195-024-01441-8

By:

Honig, Lawrence S.;
Sabbagh, Marwan N.;
van Dyck, Christopher H.;
Sperling, Reisa A.;
Hersch, Steven;
Matta, Andre;
Giorgi, Luigi;
Gee, Michelle;
Kanekiyo, Michio;
Li, David;
Purcell, Derk;
Dhadda, Shobha;
Irizarry, Michael;
Kramer, Lynn

Publication type:

Article

The search for clarity regarding "clinically meaningful outcomes" in Alzheimer disease clinical trials: CLARITY-AD and Beyond.

Published in:

Alzheimer's Research & Therapy, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13195-024-01412-z

By:

Tarawneh, Rawan;
Pankratz, Vernon S.

Publication type:

Article

Unraveling Alzheimer's: the promise of aducanumab, lecanemab, and donanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2024, v. 60, n. 1, p. 1, doi. 10.1186/s41983-024-00845-5

By:

Ameen, Taha Basit;
Kashif, Syeda Naveera;
Abbas, Syed Muhammad Iraj;
Babar, Kulsoom;
Ali, Syed Muhammad Sinaan;
Raheem, Abdul

Publication type:

Article

Advancing Alzheimer's care: a novel therapy with lecanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2023, v. 59, n. 1, p. 1, doi. 10.1186/s41983-023-00747-y

By:

Teli, Advait;
Dhande, Priti

Publication type:

Article

Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.

Published in:

JAMA: Journal of the American Medical Association, 2024, p. 1089, doi. 10.1001/jama.2024.2991

By:

Ko, Darae;
Pascual-Leone, Alvaro;
Shah, Sachin J.

Publication type:

Article

Who Should—and Can—Get Lecanemab, the New Alzheimer Disease Drug?

Published in:

JAMA: Journal of the American Medical Association, 2023, v. 330, n. 15, p. 1411, doi. 10.1001/jama.2023.14443

By:

Rubin, Rita

Publication type:

Article

Alzheimer Drug Lecanemab Gains Traditional FDA Approval.

Published in:

JAMA: Journal of the American Medical Association, 2023, v. 330, n. 6, p. 495, doi. 10.1001/jama.2023.12548

By:

Harris, Emily

Publication type:

Article

Lecanemab Gains FDA Approval for Early Alzheimer Disease.

Published in:

JAMA: Journal of the American Medical Association, 2023, v. 329, n. 5, p. 363, doi. 10.1001/jama.2022.24490

By:

Larkin, Howard D.

Publication type:

Article

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.

Published in:

Drug Discoveries & Therapeutics, 2023, v. 17, n. 6, p. 440, doi. 10.5582/ddt.2023.01215

By:

Daoran Lu;
Fangzhou Dou;
Jianjun Gao

Publication type:

Article

Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease.

Published in:

Annals of Pharmacotherapy, 2024, v. 58, n. 10, p. 1045, doi. 10.1177/10600280231218253

By:

Park, Juliane;
Simpson, Carson;
Patel, Katie

Publication type:

Article

Lecanemab-irmb.

Published in:: American Journal of Health-System Pharmacy, 2023, v. 80, n. 9, p. e81, doi. 10.1093/ajhp/zxad033
Publication type:: Article

Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer's Disease.

Published in:

Senior Care Pharmacist, 2024, v. 39, n. 2, p. 75, doi. 10.4140/TCP.n.2024.75

By:

Gettman, Lana

Publication type:

Article

P.006 Cost-effectiveness of Lecanemab for the treatment of early Alzheimer's Disease: a Canadian societal perspective.

Published in:

2025

By:

Burn, O;
Trueman, D;
Molloy, K;
Haynes, AE;
Castellano, K;
Pastor, L;
Wong, E;
Rothwell, S;
Jang, S;
Bodnar, C

Publication type:

Abstract

P.005 Real-world evidence of Lecanemab use in the United Statese.

Published in:

2025

By:

Zhao, C;
Brixner, DI;
Nair, KV;
Toyosaki, H;
Frech, FH;
Rosenbloom, MH

Publication type:

Abstract

Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.

Published in:

Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 614, doi. 10.1002/cpt.2954

By:

Dhruva, Sanket S.;
Kesselheim, Aaron S.;
Woloshin, Steven;
Ji, Robin Z.;
Lu, Zhigang;
Darrow, Jonathan J.;
Redberg, Rita F.

Publication type:

Article

JAL-TA9 のアルツハイマー病モデルマウスの認知機能改善作用.

Published in:

Folia Pharmacologica Japonica, 2024, v. 159, n. 6, p. 391, doi. 10.1254/fpj.24076

By:

Suo Zou

Publication type:

Article

Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 mg, 500 mg for Intravenous Infusion), a novel treatment for Alzheimer's disease.

Published in:

Folia Pharmacologica Japonica, 2024, v. 159, n. 3, p. 173

By:

Tetsuhiro Niidome;
Yukio Ishikawa;
Tomoo Ogawa;
Masaki Nakagawa;
Yosuke Nakamura

Publication type:

Article

Lecanemab: A Hopeful Alzheimer's Disease Treatment.

Published in:

Annals of Neurosciences, 2024, v. 31, n. 2, p. 83, doi. 10.1177/09727531231189925

By:

Mughal, Zaib Un Nisa;
Ahmed, Bisma;
Amin, Fatima;
Sadiq, Aiman;
Rangwala, Burhanuddin Sohail

Publication type:

Article

Lecanemab: The Price of a Breakthrough.

Published in:

touchREVIEWS in Neurology, 2023, v. 19, n. 1, p. 14, doi. 10.17925/USN.2023.19.1.14

By:

Wimo, Anders;
Jönsson, Linus;
Johansson, Gunilla;
Winblad, Bengt

Publication type:

Article

Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.

Published in:

Brain & Behavior, 2024, v. 14, n. 6, p. 1, doi. 10.1002/brb3.3592

By:

Hossain, Md Fahad;
Husna, Ashma Ul;
Kharel, Manish

Publication type:

Article

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.

Published in:

Alzheimer's Research & Therapy, 2022, p. 1, doi. 10.1186/s13195-022-01124-2

By:

McDade, Eric;
Cummings, Jeffrey L.;
Dhadda, Shobha;
Swanson, Chad J.;
Reyderman, Larisa;
Kanekiyo, Michio;
Koyama, Akihiko;
Irizarry, Michael;
Kramer, Lynn D.;
Bateman, Randall J.

Publication type:

Article

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01129-x

By:

Dhadda, Shobha;
Kanekiyo, Michio;
Li, David;
Swanson, Chad J.;
Irizarry, Michael;
Berry, Scott;
Kramer, Lynn D.;
Berry, Donald A.

Publication type:

Article

Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

2022

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Correction Notice

Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

2022

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Correction Notice

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

2022

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Correction Notice

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Published in:

Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00813-8

By:

Swanson, Chad J.;
Zhang, Yong;
Dhadda, Shobha;
Wang, Jinping;
Kaplow, June;
Lai, Robert Y. K.;
Lannfelt, Lars;
Bradley, Heather;
Rabe, Martin;
Koyama, Akihiko;
Reyderman, Larisa;
Berry, Donald A.;
Berry, Scott;
Gordon, Robert;
Kramer, Lynn D.;
Cummings, Jeffrey L.

Publication type:

Article

Memory Clinic Study Finds Lecanemab's Adverse Events Manageable.

Published in:

JAMA: Journal of the American Medical Association, 2025, v. 334, n. 2, p. 108, doi. 10.1001/jama.2025.7800

By:

Anderer, Samantha

Publication type:

Article

Lecanemab‐Associated Amyloid‐β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease.

Published in:

Annals of Neurology, 2025, v. 97, n. 5, p. 993, doi. 10.1002/ana.27175

By:

Noguchi‐Shinohara, Moeko;
Shuta, Kazuyoshi;
Murakami, Hidetomo;
Mori, Yukiko;
Komatsu, Junji;
Kobayashi, Chizuru;
Hersch, Steven;
Horie, Kanta;
Ono, Kenjiro

Publication type:

Article

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.

Published in:

Annals of Neurology, 2024, v. 95, n. 2, p. 288, doi. 10.1002/ana.26819

By:

Grill, Joshua D.;
Flournoy, Charlene;
Dhadda, Shobha;
Ernstrom, Karin;
Sperling, Reisa;
Molina‐Henry, Doris;
Tranotti, Kate;
Harris, Russell;
Kanekiyo, Michio;
Gee, Michelle;
Irizarry, Michael;
Kramer, Lynn;
Aisen, Paul;
Raman, Rema

Publication type:

Article

Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?

Published in:

International Journal of Molecular Sciences, 2024, v. 25, n. 7, p. 3892, doi. 10.3390/ijms25073892

By:

Høilund-Carlsen, Poul F.;
Alavi, Abass;
Castellani, Rudolph J.;
Neve, Rachael L.;
Perry, George;
Revheim, Mona-Elisabeth;
Barrio, Jorge R.

Publication type:

Article

Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.

Published in:

International Journal of Molecular Sciences, 2023, v. 24, n. 18, p. 13900, doi. 10.3390/ijms241813900

By:

Buccellato, Francesca R.;
D'Anca, Marianna;
Tartaglia, Gianluca Martino;
Del Fabbro, Massimo;
Scarpini, Elio;
Galimberti, Daniela

Publication type:

Article